By John Murawski, HOLLY SPRINGS – Pharmaceutical giant Novartis on Monday declared its $1 billion vaccine production plant, the first such facility of its kind, ready to inoculate Americans against the next global pandemic outbreak. The sprawling laboratory is more than four years in the making. It is designed to supply emergency vaccine to one […]
UPDATE 1-FDA accepts Novartis broader Menveo use application
* Menveo protects against a cause of meningitis * Novartis seeking approval in infants and toddlers * Menveo already approved for people 2-55 years ZURICH, June 16 (Reuters) – U.S. authorities have accepted Novartis’s application to broaden use of its meningitis vaccine Menveo, the Swiss drugmaker said on Thursday, giving its Vaccines and Diagnostics unit […]
Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines
DURHAM, N.C. – The Duke Human Vaccine Institute today announced a collaboration and strategic agreement with Novartis Vaccines and Diagnostics to enable the rapid development of a vaccine and accelerate preparedness in case of a pandemic virus threat such as pandemic influenza. The team, composed of Duke and Novartis investigators, will utilize resources of the […]
UPDATE 1-U.S. FDA blocks Novartis's Menveo for infants
By Katie Reid ZURICH, Jan 31 (Reuters) – Novartis AG’s (NOVN.VX) vaccine against meningococcal disease, a cause of potentially deadly meningitis, failed to get U.S. backing for use in infants between two months and 12 months of age, the Swiss drugmaker said. The news comes as a setback for Novartis’s meningitis franchise as its Vaccines […]
